









Markets
/
Stocks
/
nasdaq-krro
/

Korro Bio Inc

KRRO

12.570USD

+1.030+8.93%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

118.13MMarket Cap

LossP/E TTM



Korro Bio Inc

12.570

+1.030+8.93%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Korro Bio Inc

Currency: USD Updated: 2026-02-06

Key Insights

Korro Bio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 99 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.57.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Korro Bio Inc's Score

Industry at a Glance

Industry Ranking

99 / 392

Overall Ranking

228 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Korro Bio Inc Highlights

StrengthsRisks

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.27M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.27M.

Overvalued

The company’s latest PE is -1.33, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 11.02M shares, increasing 9.18% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 7.18K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

17.571

Target Price

+52.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Korro Bio Inc is 5.88, ranking 313 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.88

Change



Financials

5.60

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.28

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Korro Bio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Korro Bio Inc is 5.86, ranking 359 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.33, which is -57.99% below the recent high of -0.56 and -295.06% above the recent low of -5.27.

Score

Industry at a Glance

Previous score

5.86

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 99/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Korro Bio Inc is 7.00, ranking 311 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 147.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

17.000

Target Price

+38.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Korro Bio Inc

KRRO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Korro Bio Inc is 8.82, ranking 53 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 15.58 and the support level at 8.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.29

Change

1.53

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.462

Buy

RSI(14)

62.438

Neutral

STOCH(KDJ)(9,3,3)

47.214

Neutral

ATR(14)

1.251

High Vlolatility

CCI(14)

41.924

Neutral

Williams %R

35.675

Buy

TRIX(12,20)

1.806

Sell

StochRSI(14)

40.464

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

12.424

Buy

MA10

12.192

Buy

MA20

10.761

Buy

MA50

8.805

Buy

MA100

21.617

Sell

MA200

19.266

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Korro Bio Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 117.07%, representing a quarter-over-quarter increase of 17.86%. The largest institutional shareholder is Steven Cohen, holding a total of 531.97K shares, representing 5.65% of shares outstanding, with 1.84% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Atlas Venture

1.14M

New Enterprise Associates (NEA)

1.09M

Lynx1 Capital Advisors LLC

733.63K

Driehaus Capital Management, LLC

671.98K

+15.69%

Fidelity Management & Research Company LLC

563.68K

-11.82%

Platanus Investment LLC

540.16K

Point72 Asset Management, L.P.

Star Investors

531.97K

-1.50%

The Vanguard Group, Inc.

Star Investors

395.66K

+2.31%

Cormorant Asset Management, LP

465.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Korro Bio Inc is 1.27, ranking 331 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.99. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.